PL2134351T3 - Sposoby i kompozycje do przedłużonego uwalniania chromu - Google Patents

Sposoby i kompozycje do przedłużonego uwalniania chromu

Info

Publication number
PL2134351T3
PL2134351T3 PL08731918T PL08731918T PL2134351T3 PL 2134351 T3 PL2134351 T3 PL 2134351T3 PL 08731918 T PL08731918 T PL 08731918T PL 08731918 T PL08731918 T PL 08731918T PL 2134351 T3 PL2134351 T3 PL 2134351T3
Authority
PL
Poland
Prior art keywords
chromium
compositions
methods
sustained release
sustained
Prior art date
Application number
PL08731918T
Other languages
English (en)
Inventor
James Komorowski
Original Assignee
Jds Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jds Therapeutics Llc filed Critical Jds Therapeutics Llc
Publication of PL2134351T3 publication Critical patent/PL2134351T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16Inorganic salts, minerals or trace elements
    • A23L33/165Complexes or chelates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4172Imidazole-alkanecarboxylic acids, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
PL08731918T 2007-03-13 2008-03-11 Sposoby i kompozycje do przedłużonego uwalniania chromu PL2134351T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89460107P 2007-03-13 2007-03-13
EP08731918.2A EP2134351B1 (en) 2007-03-13 2008-03-11 Methods and compositions for the sustained release of chromium
PCT/US2008/056545 WO2008112706A1 (en) 2007-03-13 2008-03-11 Methods and compositions for the sustained release of chromium

Publications (1)

Publication Number Publication Date
PL2134351T3 true PL2134351T3 (pl) 2017-10-31

Family

ID=39759966

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16160735T PL3050568T3 (pl) 2007-03-13 2008-03-11 Sposoby i kompozycje do przedłużonego uwalniania chromu
PL08731918T PL2134351T3 (pl) 2007-03-13 2008-03-11 Sposoby i kompozycje do przedłużonego uwalniania chromu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL16160735T PL3050568T3 (pl) 2007-03-13 2008-03-11 Sposoby i kompozycje do przedłużonego uwalniania chromu

Country Status (6)

Country Link
US (6) US8062677B2 (pl)
EP (2) EP2134351B1 (pl)
CA (2) CA3013149C (pl)
ES (2) ES2841379T3 (pl)
PL (2) PL3050568T3 (pl)
WO (1) WO2008112706A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2676977C (en) * 2007-01-31 2016-10-04 Nutrition 21, Inc. Use of chromium histidinate for treatment of cardiometabolic disorders
EP2134351B1 (en) 2007-03-13 2016-04-27 Nutrition 21, Inc. Methods and compositions for the sustained release of chromium
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
WO2009009393A2 (en) * 2007-07-06 2009-01-15 Nutrition 21, Inc. Chromium complexes for improvement of memory and cognitive function
US7897126B2 (en) * 2007-12-28 2011-03-01 Greatpoint Energy, Inc. Catalytic gasification process with recovery of alkali metal from char
WO2011002939A1 (en) * 2009-07-01 2011-01-06 Nutrition 21, Inc. Chromium complexes as enhancers of brain glucose transporters
AU2012223282B2 (en) 2011-03-01 2017-02-02 Nutrition 21, Llc Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
AU2012273516B2 (en) * 2011-06-23 2016-05-12 Innovafood Ab Improved food composition
US20140314740A1 (en) * 2011-12-09 2014-10-23 The Johns Hopkins University Compositions and methods for the prevention or treatment of diabetic complications
US8840678B2 (en) * 2012-02-10 2014-09-23 Abbott Cardiovascular Systems Inc. Drug-eluting bioabsorbable renal artery stent for renal cancer and inflammatory disorders
WO2014028610A1 (en) 2012-08-15 2014-02-20 Tris Pharma, Inc. Methylphenidate extended release chewable tablet
WO2014151128A1 (en) * 2013-03-15 2014-09-25 Andrade Agustin Composition and method for treating neuropathy
US20140356466A1 (en) * 2013-05-31 2014-12-04 Natreon, Inc. Method for treating pain and inflammation associated with arthritis using chromium-three cation in combination with phyllanthus emblica and shilajit
JOP20200052A1 (ar) 2013-12-19 2017-06-16 Bayer Pharma AG بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c
US10183047B2 (en) 2014-05-21 2019-01-22 Natreon, Inc. Chromium-containing compositions in combination with Phyllanthus emblica and shilajit having synergistic effects for improving endothelial function and cardiovascular health
WO2016209812A1 (en) * 2015-06-23 2016-12-29 Jds Therapeutics, Llc Chromium histidinate and chromium picolinate complexes
AU2017217466A1 (en) 2016-02-11 2018-08-23 Nutrition 21, Llc Chromium containing compositions for improving health and fitness
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US10820617B1 (en) 2018-03-29 2020-11-03 Government Of The United States, As Represented By The Secretary Of The Air Force All inclusive electrolytes, vitamins, and protein powder training supplement
WO2020172262A1 (en) * 2019-02-19 2020-08-27 James Janine Chromium composition and methods thereof

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3965256A (en) 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
DK135268A (pl) 1973-02-09
US3939259A (en) 1974-05-24 1976-02-17 Anthony Pescetti Coating composition and therapeutic preparation incorporating same
US4164573A (en) 1975-06-13 1979-08-14 Galinsky Alvin M Composition and method for making a suppository for introducing a hypoglycemic agent into a mammal
DE3065342D1 (en) 1979-03-19 1983-11-24 Procter & Gamble Chromium acetylacetonate as a dietary supplement and pharmaceutical agent
US4421685A (en) 1980-03-27 1983-12-20 Eli Lilly And Company Process for producing an insulin
USRE33988E (en) 1980-08-08 1992-07-07 The United States of America as repesented by the Secretary of Agriculture Dietary supplementation with essential metal picolinates
US4315927A (en) 1980-08-08 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Dietary supplementation with essential metal picolinates
FI78616C (fi) 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4424057A (en) 1982-04-01 1984-01-03 House Hugh A Wet-dry syringe
JPS5927833A (ja) 1982-08-06 1984-02-14 Advance Res & Dev Co Ltd コレステロール乃至トリグリセリド低下剤
US4954492A (en) 1983-07-08 1990-09-04 The William Seroy Group Synthetic GTF chromium material for decreasing blood lipid levels and process therefor
US4923855A (en) 1983-07-08 1990-05-08 The William Seroy Group Synthetic GTF chromium material and process therefor
US5194615A (en) 1983-07-08 1993-03-16 The William Seroy Group Synthetic GTF chromium nicotinate material and its preparation
JPS62103012A (ja) 1985-10-23 1987-05-13 Eisai Co Ltd 多重顆粒
US5731303A (en) 1985-12-04 1998-03-24 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery compositions
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
DK179286D0 (da) 1986-04-18 1986-04-18 Nordisk Gentofte Insulinpraeparat
US5028599A (en) 1986-05-15 1991-07-02 Emory University Method of treating mycardial damage
US5032608A (en) 1986-09-10 1991-07-16 Dudrick Stanley J Method and substrate composition for treating atherosclerosis
US4921877A (en) 1986-10-27 1990-05-01 Abbott Laboratories Liquid nutritional formula for glucose intolerance
US5175156A (en) 1987-11-30 1992-12-29 Nutrition 21 Chromic picolinate treatment
US5087623A (en) 1988-05-31 1992-02-11 Nitrition 21 Chromic picolinate treatment
US5085996A (en) 1988-07-29 1992-02-04 Evans Gary W Microorganism growth acceleration medium containing an effective amount of picolinic acid or metal picolinate to promote growth of the microorganism
US5057320A (en) 1988-08-01 1991-10-15 Nutrition 21 Means and method for increasing skin respiration
US6140304A (en) 1988-09-28 2000-10-31 Eicotech Corporation Method of and nutritional and pharmaceutical compositions for reduction of hyperinsulinemia
US5087624A (en) 1989-03-21 1992-02-11 Nutrition 21 Chromic picolinate treatment
BR9105986A (pt) 1990-02-05 1992-11-10 Univ Texas Formulacao de liberacao por tempo de vitaminas,minerais e outros suplementos beneficos
US5614553A (en) 1990-07-06 1997-03-25 Albion Laboratories, Inc. Composition and method for alleviating stress in warm-blooded animals
US6099856A (en) 1992-06-15 2000-08-08 Emisphere Technologies, Inc. Active agent transport systems
US5629020A (en) 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5106836A (en) 1991-02-22 1992-04-21 Clintec Nutrition Co. Enteral diet
US5114963A (en) 1991-03-13 1992-05-19 Medicis Corporation Method of reducing serum levels of lipoprotein(A)
ES2073301T3 (es) 1991-05-20 1995-08-01 Marion Laboratories Inc Composicion multi-capa de liberacion controlada.
US5164384A (en) * 1991-06-19 1992-11-17 Metagenics, Inc. Anabolic mineral formula
US5336672A (en) 1992-07-21 1994-08-09 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Increasing egg production in poultry
IT1258491B (it) 1992-09-24 1996-02-26 Sigma Tau Ind Farmaceuti Impiego di l-carnitina e acil l-carnitine nel trattamento di pazienti affetti da aids e sindromi correlate e di pazienti asintomatici hiv- sieropositivi.
IT1256393B (it) 1992-11-17 1995-12-04 Inverni Della Beffa Spa Forme matriciali multistrato per il rilascio controllato di principi attivi
SE9203753D0 (sv) 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
IL109403A0 (en) 1993-04-22 1994-07-31 Emisphere Tech Inc Oral drug delivery compositions and methods
US5643957A (en) 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5534488A (en) 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5496827A (en) 1994-07-15 1996-03-05 Patrick; Jay Compositions for the transdermal delivery of nutrients
US5744161A (en) 1995-02-24 1998-04-28 Sabinsa Corporation Use of piperine as a bioavailability enhancer
CN1151836C (zh) 1995-03-31 2004-06-02 艾米斯菲尔技术有限公司 用作传送活性剂的化合物和组合物
US6090958A (en) 1995-03-31 2000-07-18 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6001347A (en) 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5989539A (en) 1995-03-31 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5965121A (en) 1995-03-31 1999-10-12 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5582839A (en) 1995-04-18 1996-12-10 Nutrition 21 Magnesium taurate and other mineral taurates
US6099869A (en) 1995-04-18 2000-08-08 Nutrition 21 Calcium taurate and antihypertensive drug for hypertension
US5776498A (en) 1995-11-06 1998-07-07 Nutrition 21 Magnesium taurate as an adjuvant to rapid thrombolytic therapy
US6329361B1 (en) 1995-05-12 2001-12-11 Nutrition 21 High-dose chromic picolinate treatment of type II diabetes
US5597585A (en) 1995-12-26 1997-01-28 Williams; Andrew H. Vitamin/mineral composition
US5635535A (en) 1996-04-05 1997-06-03 Wagstaff; Robert K. Method for increasing blood glucose levels
US5937597A (en) 1996-07-18 1999-08-17 Ykk Architectural Products Inc. Multi-window sash and batten attachment structure
US6197295B1 (en) 1996-09-25 2001-03-06 Viva America Marketing Corporation Dietary supplementation with, and methods for administration of yeast-derived selenium product
US6051561A (en) 1997-02-07 2000-04-18 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
US5876710A (en) 1997-02-07 1999-03-02 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
US5804688A (en) 1997-02-07 1998-09-08 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5776888A (en) 1997-02-07 1998-07-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5879681A (en) 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US5990166A (en) 1997-02-07 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6060513A (en) 1997-02-07 2000-05-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6358504B1 (en) 1997-02-07 2002-03-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5939381A (en) 1997-02-07 1999-08-17 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5707970A (en) 1997-02-12 1998-01-13 Nutrition 21 Arginine silicate complex and use thereof
US6291495B1 (en) 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US5863944A (en) 1997-04-30 1999-01-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DE19722618A1 (de) 1997-05-30 1998-12-03 Philips Patentverwaltung Hochtemperaturkondensator
CN1273531A (zh) 1997-08-08 2000-11-15 营养21 用铬/生物素治疗ⅱ型糖尿病
US5914326A (en) 1997-08-08 1999-06-22 Ambi Inc. Method for promoting weight and fat loss
US5789401A (en) 1997-08-08 1998-08-04 Nutrition 21 High-dose chromium/biotin treatment of type II diabetes
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6048846A (en) 1998-02-26 2000-04-11 Cochran; Timothy M. Compositions used in human treatment
US6245027B1 (en) 1998-04-10 2001-06-12 Noam Alperin Method of measuring intracranial pressure
US5948772A (en) * 1998-08-28 1999-09-07 Ambi Inc. Chromium picolinate compositions and uses thereof
NZ509238A (en) 1998-07-27 2003-07-25 Emisphere Tech Inc Pulmonary delivery of active agents the carrier containing acylated or sulfonated amino acids
AU5471199A (en) 1998-08-07 2000-02-28 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5980905A (en) * 1998-08-28 1999-11-09 Ambi Inc. Chromium polynicotinate compositions and uses thereof
US6376549B1 (en) * 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
CA2344246A1 (en) 1998-09-17 2000-03-23 Akesis Pharmaceuticals, Inc. Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders
ATE311373T1 (de) 1999-02-11 2005-12-15 Emisphere Tech Inc Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
WO2000050386A1 (en) 1999-02-26 2000-08-31 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
IL145546A0 (en) 1999-04-05 2002-06-30 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US6524616B1 (en) 1999-06-25 2003-02-25 Wake Forest University Health Services Compositions and methods for treating or preventing neurodegeneration and cognitive decline and dysfunction associated with alzheimer's disease, aging, other dementia related disorders and estrogen deficiency related conditions
US6261606B1 (en) 1999-09-14 2001-07-17 Natural Compounds, Ltd. Naturally extracted and synthetic hypoglycemic or hypolipidemic compositions
JP2001104702A (ja) 1999-10-01 2001-04-17 Air Liquide Japan Ltd ガスの集合回収装置および集合回収方法
DE19948361A1 (de) 1999-10-07 2001-04-12 Bsh Bosch Siemens Hausgeraete Kältegerät
US6689383B1 (en) 1999-10-08 2004-02-10 The United States Of America As Represented By The Secretary Of Agriculture Chromium-histidine complexes as nutrient supplements
WO2001032130A2 (en) 1999-11-05 2001-05-10 Emisphere Technologies, Inc. Phenyl amine carboxylic acid compounds and compositions for delivering active agents
AU1594801A (en) 1999-11-12 2001-06-06 Emisphere Technologies, Inc. Liquid heparin formulation
DE19959351A1 (de) 1999-12-09 2001-06-13 Bilstein Spezialfab Wilhelm Schneidvorrichtung mit Eigenantrieb für eine Einrichtung zum Längsteilen von durchlaufenden Materialbahnen
ATE387430T1 (de) 1999-12-16 2008-03-15 Emisphere Tech Inc Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
US7151191B2 (en) 2000-01-13 2006-12-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DE60138019D1 (de) * 2000-05-01 2009-04-30 Accera Inc Verwendung von triglyceriden mit mittellangen ketten zur behandlung und vorbeugung der alzheimerschen erkrankung
IT1318524B1 (it) 2000-05-17 2003-08-27 Ambros Pharma S R L Composizioni a rilascio controllato contenenti un principio attivo,preferibilmente melatonina, e processo di preparazione delle stesse.
CN100482637C (zh) 2000-06-29 2009-04-29 艾米斯菲尔技术有限公司 用于投递活性剂的化合物和组合物
US6365176B1 (en) 2000-08-08 2002-04-02 Functional Foods, Inc. Nutritional supplement for patients with type 2 diabetes mellitus for lipodystrophy
CA2421575C (en) 2000-09-06 2011-07-12 Emisphere Technologies, Inc. Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
AU2001296865A1 (en) 2000-09-06 2002-03-22 Emisphere Technologies, Inc. (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
EP1357977B1 (en) 2000-09-21 2004-07-21 Nutrition 21, Inc. Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia
UA77660C2 (en) 2000-10-03 2007-01-15 Compositions and methods for reducing plasma lipoprotein a level in human
AU2002232471A1 (en) * 2000-10-31 2002-05-15 Nutrition 21, Inc. Methods and compositions for the treatment of polycystic ovary syndrome with chromium complexes
AU2002230543A1 (en) * 2000-11-02 2002-05-15 Nutrition 21, Inc. Methods and compositions for the improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes and alpha lipoic acid
US6579866B2 (en) 2000-12-28 2003-06-17 Mccleary Larry Composition and method for modulating nutrient partitioning
PT1397148E (pt) 2001-02-27 2006-11-30 Nutrition 21 Inc Tratamento da dislipidemia com crómio/biotina
WO2002070438A2 (en) 2001-03-01 2002-09-12 Emisphere Technologies, Inc. Compositions for delivering bisphosphonates
CA2438849A1 (en) 2001-03-01 2002-09-12 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU2002336759A1 (en) 2001-09-21 2003-04-14 Accera, Inc. Drug targets for alzheimer's disease and other diseases associated with decreased neuronal metabolism
AU2002357729A1 (en) * 2001-11-16 2003-06-10 Nutrition 21, Inc. Trans-10, cis-12 conjugated linoleic acid isomer for the treatment of diseases
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US20050214384A1 (en) 2002-04-23 2005-09-29 Vijaya Juturu Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
US7063865B2 (en) * 2002-05-10 2006-06-20 Jeremy Park Jones Composition and method for substantially reducing the deleterious effects of alcohol on the body
US20040005368A1 (en) 2002-07-01 2004-01-08 Morris Mann Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite
US20040115265A1 (en) 2002-12-11 2004-06-17 Loutfy Benkerrour Multilayered tablet containing pravastatin and aspirin and method
US20040185119A1 (en) 2003-02-26 2004-09-23 Theuer Richard C. Method and compositions for treating gastric hyperacidity while diminishing the likelihood of producing vitamin deficiency
US7291591B2 (en) 2003-04-11 2007-11-06 All Natural Fmg, Inc. Alcohol-free transdermal insulin composition
WO2004107881A1 (en) 2003-06-04 2004-12-16 Serfontein, Willem, Jacob Nutritional compositions and use thereof
MXPA06002316A (es) 2003-09-03 2006-05-19 Boehringer Ingelheim Int Capsula que contiene granulos de sustancia activa con diferentes perfiles de liberacion.
US20050069593A1 (en) * 2003-09-29 2005-03-31 Life Time Fitness, Inc. Nutritional supplement containing 7-Keto-DHEA and conjugated linoleic acid
KR100978717B1 (ko) 2003-12-08 2010-08-30 씨펙스 파마슈티칼스, 인코포레이티드 인슐린 치료를 위한 약제 조성물 및 방법
US20060024383A1 (en) 2004-07-27 2006-02-02 Roger Berlin Compositions containing policosanol and chromium and/or chromium salts and their pharmaceutical uses
US20060062859A1 (en) 2004-08-05 2006-03-23 Kenneth Blum Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes
US20060088574A1 (en) 2004-10-25 2006-04-27 Manning Paul B Nutritional supplements
WO2006060753A2 (en) 2004-12-03 2006-06-08 Rhode Island Hospital Diagnosis and treatment of alzheimer's disease
US20060280795A1 (en) 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
BRPI0614417A2 (pt) 2005-07-28 2011-03-29 Reliant Pharmaceuticals Inc composições farmacêuticas compreendendo bloqueadores de canais de cálcio de dihidropiridina e ácidos graxos de Èmega-3 e métodos de tratamento utilizando as mesmas
US20070231260A1 (en) 2005-09-30 2007-10-04 Xenoport, Inc. Transporter-targeted methods of diagnosis and treatment
CN100446676C (zh) * 2006-03-29 2008-12-31 浙江大学 控缓释型铬的补铬饲料添加剂及其制备与使用方法
CA2676977C (en) 2007-01-31 2016-10-04 Nutrition 21, Inc. Use of chromium histidinate for treatment of cardiometabolic disorders
EP2134351B1 (en) 2007-03-13 2016-04-27 Nutrition 21, Inc. Methods and compositions for the sustained release of chromium
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
WO2009009393A2 (en) 2007-07-06 2009-01-15 Nutrition 21, Inc. Chromium complexes for improvement of memory and cognitive function
US20100262434A1 (en) 2007-12-13 2010-10-14 Shaya Steven A Method and apparatus to calculate diabetic sensitivity factors affecting blood glucose
TW201002332A (en) * 2008-07-07 2010-01-16 Univ Nat Chunghsing Composition for preventing and controlling fatty liver disease
WO2010111518A1 (en) 2009-03-27 2010-09-30 Yale University Treatment and prevention of white matter injury with katp channel activators
WO2011002939A1 (en) 2009-07-01 2011-01-06 Nutrition 21, Inc. Chromium complexes as enhancers of brain glucose transporters
AU2012223282B2 (en) 2011-03-01 2017-02-02 Nutrition 21, Llc Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders

Also Published As

Publication number Publication date
EP2134351A1 (en) 2009-12-23
US9675702B2 (en) 2017-06-13
US8062677B2 (en) 2011-11-22
ES2579229T3 (es) 2016-08-08
EP2134351B1 (en) 2016-04-27
US20190314510A1 (en) 2019-10-17
US9597404B2 (en) 2017-03-21
EP3050568A1 (en) 2016-08-03
US20150320874A1 (en) 2015-11-12
US20090155384A1 (en) 2009-06-18
PL3050568T3 (pl) 2021-06-14
CA3013149A1 (en) 2008-09-18
US9119835B2 (en) 2015-09-01
US20150320796A1 (en) 2015-11-12
US10245325B2 (en) 2019-04-02
WO2008112706A1 (en) 2008-09-18
EP3050568B1 (en) 2020-12-02
CA3013149C (en) 2021-12-07
CA2681158C (en) 2018-09-18
US20170304360A1 (en) 2017-10-26
EP2134351A4 (en) 2010-06-02
ES2841379T3 (es) 2021-07-08
CA2681158A1 (en) 2008-09-18
US20120128794A1 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
EP2134351A4 (en) METHODS AND COMPOSITIONS USED FOR PROLONGED CHROMIUM RELEASE
HRP20160902T1 (hr) Pripravci i postupci uporabe forbolskih estera
HK1145339A1 (zh) 用於定向整合的方法和組合物
ZA201001300B (en) Antigen-asjuvant compositions and methods
HK1172326A1 (en) Compounds and compositions and methods of use
DK2139466T3 (en) Magnesium Compositions and Uses Thereof
IL195619A0 (en) Compositions and methods for joininig non-conjoined iumens
EP2114460A4 (en) METHODS AND COMPOSITIONS FOR THE DISRUPTION OF BIOLOGICAL FILMS
PT2155818T (pt) Composições de juntas
EP2134352A4 (en) WNT COMPOSITIONS AND METHODS FOR THEIR USE
GB0721291D0 (en) Methods and compositions
IL211204A0 (en) Mucoadherents compositions and their use
ZA201004489B (en) Release agent formulas and methods
EP2142205A4 (en) COMPOSITIONS AND METHODS FOR INCREASING VASCULARIZATION
IL205248A0 (en) Compositions and methods for making androstenediones
GB0717376D0 (en) Composition and manufacture thereof
GB0724498D0 (en) Slow release compositions
EP1976488A4 (en) ALFUZOSIN PROLONGED RELEASE PREPARATIONS
GB0719526D0 (en) Compositions and methods
IL201766A0 (en) Compositions of (-)-e-10-oh-nt and methods for their synthesis and use
EP2247303A4 (en) HEMOSTASE MODULATING COMPOSITIONS AND USES THEREFOR
GB0715428D0 (en) Compositions and uses thereof
ZA201004894B (en) Nuctraceutical composition and methods of use
GB0701170D0 (en) Compositions and uses thereof
GB0701171D0 (en) Compositions and uses thereof